Why Pharma Keeps Misreading Advocacy Power
The industry still treats patient advocacy as a communications function. The data says it's a strategic blind spot, and the gap is widening between teams that see it and teams that don't.
Read on beehiivAdvocacy Intelligence on the forces reshaping access, policy, and patient power, plus talks and conversations from our channel. Read it. Watch it. Put it to work.
The industry still treats patient advocacy as a communications function. The data says it's a strategic blind spot, and the gap is widening between teams that see it and teams that don't.
Read on beehiivA structural shift in coverage is coming that few forecasts account for, and patients will feel it first.
Accountability is being repackaged as positioning. What that means for advocacy teams and the patients they serve.
A month-in-review of the policy and access shocks that stacked up faster than the system could absorb.
Behind every denial is an incentive structure most patients never see. We trace the conflict to its source.
More than half of patients face an initial denial. The ELAVAY data on what that does to trust, and outcomes.
The industry spent billions on patient engagement. Virginia hospitals spent the same period suing patients.
Matt Toresco's TEDx talk on lived experience, advocacy, and rebuilding the system around the people it's meant to serve.
How decision-ready intelligence changes the conversation with leadership.
The friction points that erode trust, and where advocates can intervene.
Why advocacy power is consistently underestimated inside life sciences.
The fastest explanation of what we do and why it matters.
What patient-centered innovation looks like when it reaches the C-suite.
Turning powerful insights into the kind of change leadership will fund.
Advocacy Intelligence on access, policy, and patient power, delivered to your inbox. Join the advocacy and life-sciences leaders who read it first.